Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00267202 · ClinicalTrials.gov registry record · Phase 4
Study to Evaluate the Effect of Omalizumab on Improving the Tolerability of Specific Immunotherapy in Patients With Persistent Allergic Asthma
A Phase 4 study, sponsored by Novartis.
- Completed
- Registry status
- Phase 4
- Development phase
- 275
- Enrollment target
NCT00267202 is a Phase 4 study that has completed, run by Novartis. The registered enrollment target is 275 participants.
The verdict
NCT00267202, a Phase 4 study, has completed, sponsored by Novartis.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 275 participants
- Enrollment target
Study Summary
This study is designed to investigate the use of omalizumab as a pretreatment for patients with persistent allergic asthma who are candidates for allergen immunotherapy (ie, allergy shots) and will test the hypothesis that omalizumab may reduce the rate of systemic reactions to immunotherapy in patients with persistent allergic asthma.
Interventions
- DRUG Placebo
- DRUG Immunotherapy
- DRUG Omalizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 275 participants |
| Start Date | 2005-12 |
| Est. Completion | 2008-04 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00267202
The ClinicalTrials.gov registry entry for NCT00267202 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 275 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis, which has 265 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00267202 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00267202 about?
NCT00267202 is a clinical study titled "Study to Evaluate the Effect of Omalizumab on Improving the Tolerability of Specific Immunotherapy in Patients With Persistent Allergic Asthma". This study is designed to investigate the use of omalizumab as a pretreatment for patients with persistent allergic asthma who are candidates for allergen immunotherapy (ie, allergy shots) and will test the hypothesis that omalizumab may reduce the rate of systemic reactions to immunotherapy in pati...
What is the current status of trial NCT00267202?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 275 participants. The study started on 2005-12. Estimated completion is 2008-04.
What interventions are being tested in trial NCT00267202?
The interventions under investigation include: Placebo (DRUG), Immunotherapy (DRUG), Omalizumab (DRUG).
Who is sponsoring clinical trial NCT00267202?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.